Gilead Sciences Inc. closed 7.92% below its 52-week high of $119.96, which the company achieved on March 10th.

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to ...

Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

Gilead Sciences (GILD) is currently showing above average volatility with an IV Percentile of 95% and an IV Rank of 70.73%.

J&J has a multi-year head start, but Gilead believes it can win market share by delivering a drug with better safety and at ...

A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent ...

Spoiler alert! Here's how Hulu's "The Handmaid's Tale" ends after six long seasons of June (Elisabeth Moss) in Gilead.

The data may change how patients are treated following a diagnosis for advanced triple-negative breast cancer, one expert ...

The series had introduced Elisabeth Moss as June, a mother and wife who was captured by the totalitarian fascist regime the ...